Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials

Lamanna, C., Monami, M., Marchionni, N., Mannucci, E.·2011·Diabetes, Obesity and Metabolism

Abstract

Aim: Some studies suggested that metformin could reduce cardiovascular risk to a greater extent than that determined by glucose reduction. Aim of the present meta‐analysis is to assess the effects of metformin on the incidence of cardiovascular events and mortality. Methods: An extensive search of Medline, EMBASE and the Cochrane Library (any date up to 31 October 2009) was performed for all trials containing the word ‘metformin’. Randomized trials with a duration ≥52 weeks were included. A meta‐regression analysis was also performed to identify factors associated with cardiovascular morbidity and mortality in metformin‐treated patients. Results: A total of 35 clinical trials were selected including 7171 and 11 301 participants treated with metformin and comparator, respectively, who had 451 and 775 cardiovascular (CV) events, respectively. Overall, metformin was not associated with significant harm or benefit on cardiovascular events (MH‐OR 0.94[0.82–1.07], p = 0.34). A significant benefit was observed in trials versus placebo/no therapy (MH‐OR 0.79[0.64–0.98], p = 0.031), but not in active‐comparator trials (MH‐OR 1.03[0.72–1.77], p = 0.89). Meta‐regression showed a significant correlation of the effect of metformin on cardiovascular events with trial duration and with minimum and maximum age for inclusion, meaning that the drug appeared to be more beneficial in longer trials enrolling younger patients. It is likely that metformin monotherapy is associated with improved survival (MH‐OR: 0.801[0.625–1.024], p = 0.076). However, concomitant use with sulphonylureas was associated with reduced survival (MH‐OR: 1.432[1.068–1.918], p = 0.016). Conclusion: Available evidence seems to exclude any overall harmful effect of metformin on cardiovascular risk, suggesting a possible benefit versus placebo/no treatment. The observed detrimental effect of the combination with sulphonylureas deserves further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2010.01349.x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 34 references

Cited by

See all 364

Metadata

Authors
Lamanna, C., Monami, M., Marchionni, N., & Mannucci, E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-01-24
Volume
13
Issue
3
Pages
221-228
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2050160827
Cited by
364
References
34
FWCI
14.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01349.x
The paper
Lamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011). Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01349.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.